## The ADAMs: signalling scissors in the tumour microenv

Nature Reviews Cancer 8, 932-941 DOI: 10.1038/nrc2459

Citation Report

#	Article	IF	CITATIONS
1	Shedding of Collagen XVII/BP180 in Skin Depends on Both ADAM10 and ADAM9. Journal of Biological Chemistry, 2009, 284, 23386-23396.	1.6	105
2	ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biology and Therapy, 2009, 8, 1045-1054.	1.5	79
3	Association between MMP1 and MMP9 activities and ICAM1 cleavage induced by tumor necrosis factor in stromal cell cultures from eutopic endometria of women with endometriosis. Reproduction, 2009, 138, 837-847.	1.1	35
4	Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix. Gynecologic Oncology, 2009, 114, 332-336.	0.6	23
5	The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression. Journal of Cellular Biochemistry, 2009, 106, 967-974.	1.2	29
6	The Tumor Microenvironment: The Making of a Paradigm. Cancer Microenvironment, 2009, 2, 9-17.	3.1	164
7	Shedding Light on Proteolytic Cleavage of CD44: The Responsible Sheddase and Functional Significance of Shedding. Journal of Investigative Dermatology, 2009, 129, 1321-1324.	0.3	48
8	Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer. Journal of Clinical Oncology, 2009, 27, 5287-5297.	0.8	716
9	The role of ADAMs in disease pathophysiology. Clinica Chimica Acta, 2009, 403, 31-36.	0.5	56
10	EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. Journal of Dermatological Science, 2009, 56, 148-153.	1.0	59
11	Role of ADAM and ADAMTS metalloproteinases in airway diseases. Respiratory Research, 2009, 10, 127.	1.4	43
12	Translation initiation: a critical signalling node in cancer. Expert Opinion on Therapeutic Targets, 2009, 13, 1279-1293.	1.5	47
13	ADAMs and Ectodomain Proteolytic Shedding in Leukocyte and Tumour Cell Migration. Translational Research in Biomedicine, 2009, , 83-101.	0.4	0
14	Fluorescent Substrates Useful as High Throughput Screening Tools for ADAM9. Combinatorial Chemistry and High Throughput Screening, 2010, 13, 358-365.	0.6	30
15	ADAMs and protein disulfide isomerase: the key to regulated cell-surface protein ectodomain shedding?. Biochemical Journal, 2010, 428, e3-e5.	1.7	14
16	ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. Journal of Molecular Medicine, 2010, 88, 497-505.	1.7	49
17	Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathology International, 2010, 60, 477-496.	0.6	227
18	Matrix metalloproteinases: Fold and function of their catalytic domains. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 20-28.	1.9	339

#	Article	IF	CITATIONS
19	Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 74-81.	3.3	10
20	ADAM28 is a serological and histochemical marker for nonâ€smallâ€cell lung cancers. International Journal of Cancer, 2010, 127, 1844-1856.	2.3	31
21	Design of Peptide Hydroxamateâ€Based Photoreactive Activityâ€Based Probes of Zincâ€Dependent Metalloproteases. European Journal of Organic Chemistry, 2010, 2010, 2100-2112.	1.2	13
22	Fellâ€Muir Lecture: Metalloproteinases: from demolition squad to master regulators. International Journal of Experimental Pathology, 2010, 91, 303-313.	0.6	24
23	The regulatory crosstalk between kinases and proteases in cancer. Nature Reviews Cancer, 2010, 10, 278-292.	12.8	220
24	Stimulation of Platelet-derived Growth Factor Receptor β (PDGFRβ) Activates ADAM17 and Promotes Metalloproteinase-dependent Cross-talk between the PDGFRβ and Epidermal Growth Factor Receptor (EGFR) Signaling Pathways. Journal of Biological Chemistry, 2010, 285, 25024-25032.	1.6	45
25	Pathological Neovascularization Is Reduced by Inactivation of ADAM17 in Endothelial Cells but Not in Pericytes. Circulation Research, 2010, 106, 932-940.	2.0	132
26	The Dyslexia-associated KIAA0319 Protein Undergoes Proteolytic Processing with γ-Secretase-independent Intramembrane Cleavage. Journal of Biological Chemistry, 2010, 285, 40148-40162.	1.6	36
27	Voltage-Gated Na+ Channel <i>SCN5A</i> Is a Key Regulator of a Gene Transcriptional Network That Controls Colon Cancer Invasion. Cancer Research, 2010, 70, 6957-6967.	0.4	239
28	Metzincin Proteases and Their Inhibitors: Foes or Friends in Nervous System Physiology?. Journal of Neuroscience, 2010, 30, 15337-15357.	1.7	204
29	Secreted and Membrane-Bound Isoforms of Protease ADAM9 Have Opposing Effects on Breast Cancer Cell Migration. Cancer Research, 2010, 70, 8187-8198.	0.4	56
30	Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2). Biochemical Journal, 2010, 430, 79-86.	1.7	34
31	Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. Journal of Experimental Medicine, 2010, 207, 1617-1624.	4.2	286
32	A Disintegrin and Metalloproteinase-10 (ADAM-10) Mediates DN30 Antibody-induced Shedding of the Met Surface Receptor. Journal of Biological Chemistry, 2010, 285, 26335-26340.	1.6	61
33	ADAM-15 Disintegrin-Like Domain Structure and Function. Toxins, 2010, 2, 2411-2427.	1.5	12
34	ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. Journal of Cell Science, 2010, 123, 3913-3922.	1.2	165
35	Inhibiting adenoid cystic carcinoma cells growth and metastasis by blocking the expression of ADAM 10 using RNA interference. Journal of Translational Medicine, 2010, 8, 136.	1.8	19
36	Sweetening the Pot: Adding Glycosylation to the Biomarker Discovery Equation. Clinical Chemistry, 2010, 56, 223-236.	1.5	274

#	Article	IF	CITATIONS
37	Matrix biology meets toxinology. Matrix Biology, 2010, 29, 239-247.	1.5	25
38	Biologic protease inhibitors as novel therapeutic agents. Biochimie, 2010, 92, 1681-1688.	1.3	66
39	TGFÎ <sup>2</sup> induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cells. Biochemical and Biophysical Research Communications, 2010, 402, 449-454.	1.0	28
40	Connective tissue growth factor is a substrate of ADAM28. Biochemical and Biophysical Research Communications, 2010, 402, 651-657.	1.0	36
41	Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell, 2010, 141, 52-67.	13.5	4,103
42	Extracellular matrix turnover and signaling during cardiac remodeling following MI: Causes and consequences. Journal of Molecular and Cellular Cardiology, 2010, 48, 558-563.	0.9	95
43	Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. Journal of Experimental Medicine, 2011, 208, 1459-1471.	4.2	322
44	Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities. Integrative Biology (United Kingdom), 2011, 3, 422-438.	0.6	77
45	Disintegrin-like/cysteine-rich domains of the reprolysin HF3: Site-directed mutagenesis reveals essential role of specific residues. Biochimie, 2011, 93, 345-351.	1.3	22
46	Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells. European Journal of Cancer, 2011, 47, 934-945.	1.3	33
47	ADAM9 Inhibition Increases Membrane Activity of ADAM10 and Controls α-Secretase Processing of Amyloid Precursor Protein. Journal of Biological Chemistry, 2011, 286, 40443-40451.	1.6	54
48	Glioblastoma cells: A heterogeneous and fatal tumor interacting with the parenchyma. Life Sciences, 2011, 89, 532-539.	2.0	100
49	Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer. World Journal of Gastrointestinal Oncology, 2011, 3, 79.	0.8	22
50	Extracellular Matrix Microenvironment in Glioma Progression. , 0, , .		23
51	PKCα and PKCδ Regulate ADAM17-Mediated Ectodomain Shedding of Heparin Binding-EGF through Separate Pathways. PLoS ONE, 2011, 6, e17168.	1.1	53
52	Metalloproteases/anti-metalloproteases imbalance in chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2011, 17, S11-S19.	1.2	69
53	Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer. Anesthesia and Analgesia, 2011, 113, 1353-1364.	1.1	99
54	Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS Journal, 2011, 278, 16-27.	2.2	1,305

#	Article	IF	CITATIONS
55	Enzymatic toxins from snake venom: structural characterization and mechanism of catalysis. FEBS Journal, 2011, 278, 4544-4576.	2.2	233
56	A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17. Oncogene, 2011, 30, 611-618.	2.6	55
57	Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL. Leukemia, 2011, 25, 1564-1569.	3.3	39
58	Cellâ€type Selective Phototoxicity Achieved with Chlorophyllâ€a Derived Photosensitizers in a Coâ€culture System of Primary Human Tumor and Normal Lung Cells. Photochemistry and Photobiology, 2011, 87, 1405-1418.	1.3	28
59	The "A Disintegrin And Metalloproteases―ADAM10 and ADAM17: Novel drug targets with therapeutic potential?. European Journal of Cell Biology, 2011, 90, 527-535.	1.6	256
60	Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment. Experimental Hematology, 2011, 39, 546-557.e8.	0.2	20
61	Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry. Journal of Medicinal Chemistry, 2011, 54, 5955-5980.	2.9	529
62	Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clinical and Experimental Metastasis, 2011, 28, 793-802.	1.7	49
63	Functional interplay between tetraspanins and proteases. Cellular and Molecular Life Sciences, 2011, 68, 3323-3335.	2.4	71
64	ADAM12 and ADAM17 Gene Expression in Laser-capture Microdissected and Non-microdissected Breast Tumors. Pathology and Oncology Research, 2011, 17, 375-385.	0.9	9
65	The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?. Clinical Proteomics, 2011, 8, 9.	1.1	164
66	A Functional Role for ADAM10 in Human Immunodeficiency Virus Type-1 Replication. Retrovirology, 2011, 8, 32.	0.9	23
67	Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo. Molecular Neurodegeneration, 2011, 6, 36.	4.4	93
68	Protease profiling of liver fibrosis reveals the ADAM metallopeptidase with thrombospondin type 1 motif, 1 as a central activator of transforming growth factor beta. Hepatology, 2011, 54, 2173-2184.	3.6	66
69	Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form. International Journal of Cancer, 2011, 129, 791-798.	2.3	19
70	Extracellular Matrix Degradation and Remodeling in Development and Disease. Cold Spring Harbor Perspectives in Biology, 2011, 3, a005058-a005058.	2.3	1,597
71	Unsaturated Fatty Acids Drive Disintegrin and Metalloproteinase (ADAM)-dependent Cell Adhesion, Proliferation, and Migration by Modulating Membrane Fluidity. Journal of Biological Chemistry, 2011, 286, 26931-26942.	1.6	49
72	Shedding of the Mer Tyrosine Kinase Receptor Is Mediated by ADAM17 Protein through a Pathway Involving Reactive Oxygen Species, Protein Kinase CĨ´, and p38 Mitogen-activated Protein Kinase (MAPK). Journal of Biological Chemistry, 2011, 286, 33335-33344.	1.6	228

#	Article	IF	CITATIONS
73	Aberrant Expression of Disintegrin-Metalloprotease Proteins in the Formation and Progression of Uterine Cervical Cancer. Pathobiology, 2011, 78, 149-161.	1.9	4
74	RNF41 (Nrdp1) controls type 1 cytokine receptor degradation and ectodomain shedding. Journal of Cell Science, 2011, 124, 921-932.	1.2	58
75	Mammary Gland Reprogramming: Metalloproteinases Couple Form with Function. Cold Spring Harbor Perspectives in Biology, 2011, 3, a004333-a004333.	2.3	43
76	Epidermal Growth Factor (EGF) Ligand Release by Substrate-specific A Disintegrin and Metalloproteases (ADAMs) Involves Different Protein Kinase C (PKC) Isoenzymes Depending on the Stimulus. Journal of Biological Chemistry, 2011, 286, 17704-17713.	1.6	41
77	The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma. Carcinogenesis, 2011, 32, 1713-1723.	1.3	46
78	The Cytosolic Domain of Protein-tyrosine Kinase 7 (PTK7), Generated from Sequential Cleavage by a Disintegrin and Metalloprotease 17 (ADAM17) and γ-Secretase, Enhances Cell Proliferation and Migration in Colon Cancer Cells. Journal of Biological Chemistry, 2012, 287, 25001-25009.	1.6	56
79	BACE1 Dependent Neuregulin Processing: Review. Current Alzheimer Research, 2012, 9, 178-183.	0.7	62
80	Overview of the Matrisome–An Inventory of Extracellular Matrix Constituents and Functions. Cold Spring Harbor Perspectives in Biology, 2012, 4, a004903-a004903.	2.3	942
81	Effect of ADAM28 on Carcinoma Cell Metastasis by Cleavage of von Willebrand Factor. Journal of the National Cancer Institute, 2012, 104, 906-922.	3.0	87
82	ADAM proteins, their ligands, and clinical implications. Neurology, 2012, 78, 914-920.	1.5	15
83	A disintegrin and metalloproteases: Molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis, 2012, 224, 302-308.	0.4	47
84	Cellâ€surface Metalloprotease <scp>ADAM12</scp> is Internalized by a Clathrin―and Grb2â€dependent Mechanism. Traffic, 2012, 13, 1532-1546.	1.3	19
85	TACE Activation by MAPK-Mediated Regulation of Cell Surface Dimerization and TIMP3 Association. Science Signaling, 2012, 5, ra34.	1.6	129
86	Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function. Journal of Cell Science, 2012, 125, 6084-6093.	1.2	33
87	Monoubiquitination of pro-amphiregulin regulates its endocytosis and ectodomain shedding. Biochemical and Biophysical Research Communications, 2012, 420, 315-320.	1.0	12
88	Alsophinase, a new P-III metalloproteinase with α-fibrinogenolytic and hemorrhagic activity from the venom of the rear-fanged Puerto Rican Racer Alsophis portoricensis (Serpentes: Dipsadidae). Biochimie, 2012, 94, 1189-1198.	1.3	34
89	Identification of Novel Interaction between ADAM17 (a Disintegrin and Metalloprotease 17) and Thioredoxin-1. Journal of Biological Chemistry, 2012, 287, 43071-43082.	1.6	33
	ADAM17 Silen sing in Meuros Colon Consinence Colley The Effect on Tymesistical Cytokings and		

#	Article	IF	CITATIONS
91	The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress. Oncogene, 2012, 31, 3621-3634.	2.6	66
92	Prognostic value of ADAM17 in human gastric cancer. Medical Oncology, 2012, 29, 2684-2690.	1.2	28
93	Functional Analysis of a Breast Cancer-Associated Mutation in the Intracellular Domain of the Metalloprotease ADAM12. PLoS ONE, 2012, 7, e37628.	1.1	4
94	The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth. Frontiers in Pharmacology, 2012, 3, 164.	1.6	14
95	1.1 Extracellular matrix: a functional scaffold. , 2012, , 3-20.		12
96	Role of HB-EGF in cancer. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2012, , .	0.1	1
97	Nardilysin and ADAM proteases promote gastric cancer cell growth by activating intrinsic cytokine signalling via enhanced ectodomain shedding of TNFâ€Î±. EMBO Molecular Medicine, 2012, 4, 396-411.	3.3	40
98	Molecular Pathology of Cancer Metastasis: Suggestions for Future Therapy. , 2012, , 469-515.		2
99	Genetic Variations in the ADAMTS12 Gene are Associated with Schizophrenia in Puerto Rican Patients of Spanish Descent. NeuroMolecular Medicine, 2012, 14, 53-64.	1.8	13
100	Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics. Acta Histochemica, 2012, 114, 131-139.	0.9	18
101	Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology, 2012, 60, 187-198.	1.6	52
102	Proteolytic processing of the protein tyrosine phosphatase α extracellular domain is mediated by ADAM17/TACE. European Journal of Cell Biology, 2012, 91, 687-693.	1.6	9
103	Free Energy Calculations on Snake Venom Metalloproteinase BaP1. Chemical Biology and Drug Design, 2012, 79, 990-1000.	1.5	5
104	Neural crest delamination and migration: From epithelium-to-mesenchyme transition to collective cell migration. Developmental Biology, 2012, 366, 34-54.	0.9	439
105	Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer. World Journal of Surgical Oncology, 2012, 10, 42.	0.8	9
106	Endothelinâ€1 stimulates motility of head and neck squamous carcinoma cells by promoting stromal–epithelial interactions. International Journal of Cancer, 2012, 130, 40-47.	2.3	35
107	Involvement of TACE/ADAM17 and ADAM10 in etoposideâ€induced apoptosis of germ cells in rat spermatogenesis. Journal of Cellular Physiology, 2012, 227, 829-838.	2.0	16
108	ADAM17 promotes glioma cell malignant phenotype. Molecular Carcinogenesis, 2012, 51, 150-164.	1.3	54

#	Article	IF	CITATIONS
109	Molecular Profiling of ADAM12 and ADAM17 Genes in Human Malignant Melanoma. Pathology and Oncology Research, 2013, 19, 755-762.	0.9	7
110	Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype. Breast Cancer Research and Treatment, 2013, 139, 691-703.	1.1	24
111	Src Plays a Key Role in ADAM28 Expression in v-src–Transformed Epithelial Cells and Human Carcinoma Cells. American Journal of Pathology, 2013, 183, 1667-1678.	1.9	9
112	Generation of Soluble <scp>NKG</scp> 2 <scp>D</scp> Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications. Scandinavian Journal of Immunology, 2013, 78, 120-129.	1.3	163
113	Down-regulation of endothelial protein C receptor shedding by persicarin and isorhamnetin-3-O-galactoside. Thrombosis Research, 2013, 132, e58-e63.	0.8	7
114	The Concise Guide to <scp>PHARMACOLOGY</scp> 2013/14: Enzymes. British Journal of Pharmacology, 2013, 170, 1797-1867.	2.7	416
115	HIV Nef, Paxillin, and Pak1/2 Regulate Activation and Secretion of TACE/ADAM10 Proteases. Molecular Cell, 2013, 49, 668-679.	4.5	83
116	Membrane-Associated Matrix Proteolysis and Heart Failure. Circulation Research, 2013, 112, 195-208.	2.0	140
117	Oncogenic H-Ras Reprograms Madin-Darby Canine Kidney (MDCK) Cell-derived Exosomal Proteins Following Epithelial-Mesenchymal Transition. Molecular and Cellular Proteomics, 2013, 12, 2148-2159.	2.5	167
118	Canonical Transforming Growth Factor-β Signaling Regulates Disintegrin Metalloprotease Expression in Experimental Renal Fibrosis via miR-29. American Journal of Pathology, 2013, 183, 1885-1896.	1.9	66
119	Ectodomain shedding of CD200 from the B-CLL cell surface is regulated by ADAM28 expression. Leukemia Research, 2013, 37, 816-821.	0.4	28
120	Potentiation of radiotherapy by a localized antiangiogenic gene therapy. Radiotherapy and Oncology, 2013, 107, 252-258.	0.3	13
121	Perturbation of invadolysin disrupts cell migration in zebrafish (Danio rerio). Experimental Cell Research, 2013, 319, 1198-1212.	1.2	7
122	The secreted <i>AdamTS-A</i> metalloprotease is required for collective cell migration. Development (Cambridge), 2013, 140, 1981-1993.	1.2	54
123	IL-1 and EGF regulate expression of genes important in inflammation and cancer. Cytokine, 2013, 62, 22-33.	1.4	60
124	Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. Critical Reviews in Biochemistry and Molecular Biology, 2013, 48, 222-272.	2.3	622
125	Human breast cancer-associated fibroblasts enhance cancer cell proliferation through increased TGF-1± cleavage by ADAM17. Cancer Letters, 2013, 336, 240-246.	3.2	34
126	ADAM22 as a Prognostic and Therapeutic Drug Target in the Treatment of Endocrine-Resistant Breast Cancer. Vitamins and Hormones, 2013, 93, 307-321.	0.7	19

		CITATION REPORT		
#	Article		IF	CITATIONS
127	Gallic acid: Molecular rival of cancer. Environmental Toxicology and Pharmacology, 201	3, 35, 473-485.	2.0	266
128	Collective cell migration of epithelial and mesenchymal cells. Cellular and Molecular Lif 2013, 70, 3481-3492.	e Sciences,	2.4	132
129	Colon tumour secretopeptidome: Insights into endogenous proteolytic cleavage event tumour microenvironment. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2 2396-2407.	s in the colon 013, 1834,	1.1	31
130	SecretePipe: A Screening Pipeline for Secreted Proteins with Competence to Identify P Membrane-Bound Shed Markers. Journal of Proteome Research, 2013, 12, 1235-1244.	otential	1.8	4
131	Overexpression of ADAM9 Promotes Colon Cancer Cells Invasion. Journal of Investigat 2013, 26, 127-133.	ive Surgery,	0.6	17
132	Solution of Working Space about the 4-DOF Parallel Mechanism by ADAMS. Applied M Materials, 0, 372, 602-607.	echanics and	0.2	0
133	LRP-1: A Checkpoint for the Extracellular Matrix Proteolysis. BioMed Research Internati 2013, 1-7.	onal, 2013,	0.9	92
134	Deletion of Cdc42 Enhances ADAM17-Mediated Vascular Endothelial Growth Factor Re Shedding and Impairs Vascular Endothelial Cell Survival and Vasculogenesis. Molecular Biology, 2013, 33, 4181-4197.	eceptor 2 and Cellular	1.1	42
135	An Association Study on <i><scp>ADAM</scp>10</i> Promoter Polymorphisms and A Cerebral Infarction in a Chinese Population. CNS Neuroscience and Therapeutics, 2013	therosclerotic , 19, 785-794.	1.9	29
136	Regulated ADAM17-dependent EGF family ligand release by substrate-selecting signalin Proceedings of the National Academy of Sciences of the United States of America, 201	ng pathways. 3, 110, 9776-9781.	3.3	74
137	Human Antigen R-mediated mRNA Stabilization Is Required for Ultraviolet B-induced A Amphiregulin in Keratinocytes. Journal of Biological Chemistry, 2013, 288, 10338-1034	utoinduction of 48.	1.6	12
138	Activity of ADAM17 (a Disintegrin and Metalloprotease 17) Is Regulated by Its Noncata Secondary Structure of its Substrates. Journal of Biological Chemistry, 2013, 288, 228	alytic Domains and 71-22879.	1.6	36
139	ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the p invasion and migration of HepG2 cells. Oncology Reports, 2013, 30, 1715-1722.	roliferation,	1.2	26
140	Systemic Overexpression of TNFα-converting Enzyme Does Not Lead to Enhanced She Vivo. PLoS ONE, 2013, 8, e54412.	dding Activity In	1.1	37
141	ADAM Metalloproteinases. , 2013, , 1086-1094.			2
142	ADAM17, Tumor Necrosis Factor Î $\pm$ -Convertase. , 2013, , 1126-1130.			1
143	Deletion of Nardilysin Prevents the Development of Steatohepatitis and Liver Fibrotic OONE, 2014, 9, e98017.	Changes. PLoS	1.1	16
144	ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 posi cancer. Oncotarget, 2014, 5, 6633-6646.	tive breast	0.8	66

#	Article	IF	CITATIONS
145	Extravillous Trophoblast-Associated ADAM12 Exerts Pro-Invasive Properties, Including Induction of Integrin Beta 1-Mediated Cellular Spreading1. Biology of Reproduction, 2014, 90, 101.	1.2	36
146	A role for STEAP2 in prostate cancer progression. Clinical and Experimental Metastasis, 2014, 31, 909-920.	1.7	48
147	Structure-Function Relationship of Modular Domains of P-III Class Snake Venom Metalloproteinases. , 2014, , 1-22.		0
148	N-Glycosylation Regulates ADAM8 Processing and Activation. Journal of Biological Chemistry, 2014, 289, 33676-33688.	1.6	21
149	The role of proteases in regulating Eph/ephrin signaling. Cell Adhesion and Migration, 2014, 8, 294-307.	1.1	41
150	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Frontiers in Immunology, 2014, 5, 122.	2.2	75
151	A <sub>1</sub> adenosine receptor–stimulated exocytosis in bladder umbrella cells requires phosphorylation of ADAM17 Ser-811 and EGF receptor transactivation. Molecular Biology of the Cell, 2014, 25, 3798-3812.	0.9	15
152	The endothelin axis in head and neck cancer: a promising therapeutic opportunity?. Journal of Oral Pathology and Medicine, 2014, 43, 395-404.	1.4	16
153	Cudratricusxanthone A inhibits endothelial protein C receptor shedding in vitro and in vivo. Animal Cells and Systems, 2014, 18, 9-16.	0.8	1
154	A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression. Journal of International Medical Research, 2014, 42, 611-618.	0.4	28
155	Blocking Hedgehog release from pancreatic cancer cells increases paracrine signaling potency. Journal of Cell Science, 2014, 128, 129-39.	1.2	24
156	miR-221/222 control luminal breast cancer tumor progression by regulating different targets. Cell Cycle, 2014, 13, 1811-1826.	1.3	38
157	ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. Cell Reports, 2014, 7, 1940-1955.	2.9	90
158	Glycosylation of a disintegrin and metalloprotease 17 affects its activity and inhibition. Analytical Biochemistry, 2014, 449, 68-75.	1.1	18
159	Exendin-4 inhibits endothelial protein C receptor shedding in vitro and in vivo. Pharmacological Research, 2014, 84, 18-25.	3.1	5
160	Relationships between TIMP-1, CAIX, and clinical outcomes in Egyptian breast cancer. Comparative Clinical Pathology, 2014, 23, 907-916.	0.3	0
161	Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression. Medical Oncology, 2014, 31, 884.	1.2	30
162	ADAM17 mediates OSCC development in an orthotopic murine model. Molecular Cancer, 2014, 13, 24.	7.9	16

#	Article	IF	CITATIONS
163	Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS. Journal of Molecular and Cellular Cardiology, 2014, 66, 167-176.	0.9	263
164	Stimuli-sensitive nanopreparations for combination cancer therapy. Journal of Controlled Release, 2014, 190, 352-370.	4.8	299
165	Regulation of Receptor Tyrosine Kinase Ligand Processing. Cold Spring Harbor Perspectives in Biology, 2014, 6, a008995-a008995.	2.3	25
166	Architecture and function of metallopeptidase catalytic domains. Protein Science, 2014, 23, 123-144.	3.1	159
167	Review: The ADAM metalloproteinases – Novel regulators ofÂtrophoblast invasion?. Placenta, 2014, 35, S57-S63.	0.7	52
168	Pericellular proteolysis in cancer. Genes and Development, 2014, 28, 2331-2347.	2.7	154
169	Remodelling the extracellular matrix in development and disease. Nature Reviews Molecular Cell Biology, 2014, 15, 786-801.	16.1	3,082
170	Senescenceâ€associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding. FASEB Journal, 2014, 28, 4847-4856.	0.2	50
171	ADAM10 Is the Major Sheddase Responsible for the Release of Membrane-associated Meprin A. Journal of Biological Chemistry, 2014, 289, 13308-13322.	1.6	49
172	Sulforaphane inhibits endothelial protein C receptor shedding in vitro and in vivo. Vascular Pharmacology, 2014, 63, 13-18.	1.0	6
173	Differential expression and localization of ADAM10 and ADAM17 during rat spermatogenesis suggest a role in germ cell differentiation. Biological Research, 2014, 47, 31.	1.5	12
174	Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role forÂcathepsin S. Nature Cell Biology, 2014, 16, 876-888.	4.6	300
175	Piperlonguminine Downregulates Endothelial Protein C Receptor Shedding In Vitro and In Vivo. Inflammation, 2014, 37, 435-442.	1.7	6
176	Apparent Reduction of ADAM10 in Scrapie-Infected Cultured Cells and in the Brains of Scrapie-Infected Rodents. Molecular Neurobiology, 2014, 50, 875-887.	1.9	10
177	ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma. Tumor Biology, 2014, 35, 7575-7586.	0.8	21
178	Withaferin A is an inhibitor of endothelial protein C receptor shedding in vitro and in vivo. Food and Chemical Toxicology, 2014, 68, 23-29.	1.8	13
179	Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells. Biochemical and Biophysical Research Communications, 2014, 448, 308-314.	1.0	68
180	ADAM10 is required for SCF-induced mast cell migration. Cellular Immunology, 2014, 290, 80-88.	1.4	14

#	Article	IF	CITATIONS
181	Effects of <scp>ADAM</scp> 10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma. Cancer Science, 2015, 106, 1506-1514.	1.7	35
182	Effect of A disintegrin and metalloproteinase 10 gene silencing on the proliferation, invasion and migration of the human tongue squamous cell carcinoma cell line TCA8113. Molecular Medicine Reports, 2015, 11, 212-218.	1.1	7
183	RNAi-mediated A disintegrin and metalloproteinase 9 gene silencing inhibits the tumor growth of non-small lung cancer in vitro and in vivo. Molecular Medicine Reports, 2015, 12, 1197-1204.	1.1	10
185	Expression profile of ADAM10 and ADAM17 in allergic rhinitis. International Forum of Allergy and Rhinology, 2015, 5, 1036-1041.	1.5	6
186	Relationship between single-nucleotide polymorphism of matrix metalloproteinase-2 gene and colorectal cancer and gastric cancer susceptibility: a meta-analysis. OncoTargets and Therapy, 2015, 8, 861.	1.0	9
187	ADAM17 Promotes Motility, Invasion, and Sprouting of Lymphatic Endothelial Cells. PLoS ONE, 2015, 10, e0132661.	1.1	19
188	Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. British Journal of Cancer, 2015, 112, 1895-1903.	2.9	52
189	Key participants of the tumor microenvironment of the prostate: An approach of the structural dynamic of cellular elements and extracellular matrix components during epithelial–stromal transition. Acta Histochemica, 2015, 117, 4-13.	0.9	20
190	ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor–initiating cells. Neuro-Oncology, 2015, 17, 1095-1105.	0.6	59
191	ADAM8 as a drug target in pancreatic cancer. Nature Communications, 2015, 6, 6175.	5.8	85
192	The sorting protein PACS-2 promotes ErbB signalling by regulating recycling of the metalloproteinase ADAM17. Nature Communications, 2015, 6, 7518.	5.8	41
193	Charting Immune Signaling Proteomes En Route to New Therapeutic Strategies. Cancer Immunology Research, 2015, 3, 714-720.	1.6	7
194	Metalloproteinases: A parade of functions in matrix biology and an outlook for the future. Matrix Biology, 2015, 44-46, 1-6.	1.5	156
195	Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5366-5371.	3.3	52
196	Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. Biomarkers in Medicine, 2015, 9, 363-375.	0.6	11
197	The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells. Neuro-Oncology, 2015, 17, 1474-1485.	0.6	48
198	Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells. Molecular and Cellular Proteomics, 2015, 14, 2213-2228.	2.5	82
199	Epithelial cell ADAM17 activation by Helicobacter pylori: role of ADAM17 C-terminus and Threonine-735 phosphorylation. Microbes and Infection, 2015, 17, 205-214.	1.0	10

#	Article	IF	CITATIONS
200	Charge-Triggered Membrane Insertion of Matrix Metalloproteinase-7, Supporter of Innate Immunity and Tumors. Structure, 2015, 23, 2099-2110.	1.6	24
201	ADAM10: a new player in breast cancer progression?. British Journal of Cancer, 2015, 113, 945-951.	2.9	61
202	High-throughput protease activity cytometry reveals dose-dependent heterogeneity in PMA-mediated ADAM17 activation. Integrative Biology (United Kingdom), 2015, 7, 513-524.	0.6	18
203	Stanford-A acute aortic dissection, inflammation, and metalloproteinases: A review. Annals of Medicine, 2015, 47, 441-446.	1.5	100
204	Nucleotide-Induced Membrane-Proximal Proteolysis Controls the Substrate Specificity of T Cell Ecto–ADP-Ribosyltransferase ARTC2.2. Journal of Immunology, 2015, 195, 2057-2066.	0.4	17
205	Matrix metalloproteinases in destructive lung disease. Matrix Biology, 2015, 44-46, 167-174.	1.5	133
206	Aspalathin and nothofagin from rooibos (Aspalathus linearis) inhibit endothelial protein C receptor shedding in vitro and in vivo. FìtoterapĂ¬Ă¢, 2015, 100, 179-186.	1.1	16
207	ADAM17 regulates IL-1 signaling by selectively releasing IL-1 receptor type 2 from the cell surface. Cytokine, 2015, 71, 238-245.	1.4	24
208	Extracellular Matrix (ECM) Molecules. , 2015, , 25-45.		19
209	Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression. Oncogene, 2015, 34, 3283-3295.	2.6	52
210	Matrix Metalloproteinases in Non-Neoplastic Disorders. International Journal of Molecular Sciences, 2016, 17, 1178.	1.8	68
211	Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression. International Journal of Biological Sciences, 2016, 12, 302-313.	2.6	83
212	Proteolysis-a characteristic of tumor-initiating cells in murine metastatic breast cancer. Oncotarget, 2016, 7, 58244-58260.	0.8	9
213	Immunohistochemical study on ADAM33 in sinonasal inverted papillomas and squamous cell carcinomas of the larynx. Archives of Medical Science, 2016, 1, 89-94.	0.4	3
214	ADAM and ADAMTS Family Proteins and Snake Venom Metalloproteinases: A Structural Overview. Toxins, 2016, 8, 155.	1.5	111
215	ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. Oncotarget, 2016, 7, 10243-10254.	0.8	27
216	Proteolytic processing of Neuregulin-1. Brain Research Bulletin, 2016, 126, 178-182.	1.4	37
217	Protease inhibition as new therapeutic strategy for GI diseases. Gut, 2016, 65, 1215-1224.	6.1	171

ARTICLE IF CITATIONS # Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven 218 5.8 36 cellular senescence. Nature Communications, 2016, 7, 13719. Metalloproteinases: a Functional Pathway for Myeloid Cells. Microbiology Spectrum, 2016, 4, . 1.2 220 Cancer – Proteases in the Progression and Metastasis. , 2016, , 753-762. 0 Sorting Motifs in the Cytoplasmic Tail of the Immunomodulatory E3/49K Protein of Species D Adenoviruses Modulaté Cell Surface Expression and Ectodomain Shedding. Journal of Biological Chemistry, 2016, 291, 6796-6812. ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to 222 2.1 50 NKG2D-mediated killing. Oncolmmunology, 2016, 5, e1123367. Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 4428-4439. 3.2 Suppressive effects of polyozellin on endothelial protein C receptor shedding via inhibiting TACE 224 1.1 4 activity and MAP kinases. Fìtoterapìâ, 2016, 108, 26-32. TIMP3 Modulates GHR Abundance and GH Sensitivity. Molecular Endocrinology, 2016, 30, 587-599. 3.7 10 Plasticity of Cancer Cell Invasionâ€" Mechanisms and Implications for Therapy. Advances in Cancer 226 1.9 71 Research, 2016, 132, 209-264. Tumor macrophages are pivotal constructors of tumor collagenous matrix. Journal of Experimental 4.2 Medicine, 2016, 213, 2315-2331. An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor 228 4.2 55 growth. Journal of Experimental Medicine, 2016, 213, 1741-1757. ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation. International Journal of 229 1.4 Oncology, 2016, 49, 682-690. Membrane-anchored proteases in endothelial cell biology. Current Opinion in Hematology, 2016, 23, 230 1.2 18 243-252. Suppressive Effects of Pelargonidin on Endothelial Protein C Receptor Shedding via the Inhibition of 1.5 TACE Activity and MAP Kinases. The American Journal of Chinese Medicine, 2016, 44, 771-784. An improved fluorescent substrate for assaying soluble and membrane-associated ADAM family 232 1.1 3 member activities. Analytical Biochemistry, 2016, 507, 13-17. Epithelial Cell-Derived a Disintegrin and Metalloproteinase-17 Confers Resistance to Colonic 30 Inflammation Through EGFR Activation. EBioMedicine, 2016, 5, 114-124. HIV-Nef and ADAM17-Containing Plasma Extracellular Vesicles Induce and Correlate with Immune 234 2.7 80 Pathogenesis in Chronic HIV Infection. EBioMedicine, 2016, 6, 103-113. Inhibitory effects of three diketopiperazines from marine-derived bacteria on endothelial protein C 1.1 receptor shedding in human endothelial cells and mice. FA¬toterapA¬A¢, 2016, 110, 181-188.

#	Article	IF	CITATIONS
236	<scp>ADAM</scp> 23 is downregulated in side population and suppresses lung metastasis of lung carcinoma cells. Cancer Science, 2016, 107, 433-443.	1.7	25
237	Structure-Function Relationship of Modular Domains of P-III Class Snake Venom Metalloproteinases. , 2016, , 185-209.		1
238	Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models. European Journal of Medicinal Chemistry, 2016, 111, 193-201.	2.6	40
239	TspanC8 Tetraspanins and A Disintegrin and Metalloprotease 10 (ADAM10) Interact via Their Extracellular Regions. Journal of Biological Chemistry, 2016, 291, 3145-3157.	1.6	86
240	Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer Metastasis. Cancer Microenvironment, 2016, 9, 45-61.	3.1	26
241	Stimuli-Sensitive Nanopreparations: Overview. , 2016, , 1-48.		0
242	Mechanobiology of cell migration in the context of dynamic two-way cell–matrix interactions. Journal of Biomechanics, 2016, 49, 1355-1368.	0.9	42
243	ADAM Proteases and Gastrointestinal Function. Annual Review of Physiology, 2016, 78, 243-276.	5.6	61
244	Fluorescent Analogue of Batimastat Enables Imaging of α-Secretase in Living Cells. ACS Chemical Neuroscience, 2016, 7, 40-45.	1.7	6
245	Proteases decode the extracellular matrix cryptome. Biochimie, 2016, 122, 300-313.	1.3	63
246	Cigarette smoke extracts induced the colon cancer migration via regulating epithelial mesenchymal transition and metastatic genes in human colon cancer cells. Environmental Toxicology, 2017, 32, 690-704.	2.1	17
247	Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma. Clinical and Translational Oncology, 2017, 19, 58-66.	1.2	7
248	Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer. Molecular Cancer, 2017, 16, 32.	7.9	39
249	Angiogenesis regulation by nanocarriers bearing RNA interference. Advanced Drug Delivery Reviews, 2017, 119, 3-19.	6.6	26
250	Characterization of the catalytic properties of the membrane-anchored metalloproteinase ADAM9 in cell-based assays. Biochemical Journal, 2017, 474, 1467-1479.	1.7	16
251	Nardilysin regulates inflammation, metaplasia, and tumors in murine stomach. Scientific Reports, 2017, 7, 43052.	1.6	13
252	Nitric-oxide synthase trafficking inducer is a pleiotropic regulator of endothelial cell function and signaling. Journal of Biological Chemistry, 2017, 292, 6600-6620.	1.6	45
253	Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity. Journal of Hepatology, 2017, 66, 1130-1137.	1.8	32

#	ARTICLE Astragaloside IV inhibits PMA-induced FPCR shedding through MAPKs and PKC nathway	IF	CITATIONS
254	Immunopharmacology and Immunotoxicology, 2017, 39, 148-156.	1.1	7
255	Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma. Hematology, 2017, 22, 527-535.	0.7	14
256	Suppressive effects of dabrafenibÂon endothelial protein C receptor shedding. Archives of Pharmacal Research, 2017, 40, 282-290.	2.7	3
257	Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis. Oncogene, 2017, 36, 5058-5067.	2.6	13
258	Riding the metalloproteinase roller coaster. Journal of Biological Chemistry, 2017, 292, 7708-7717.	1.6	22
259	ADAM9 is present at endothelial cell - cell junctions and regulates monocyte – endothelial transmigration. Biochemical and Biophysical Research Communications, 2017, 493, 1057-1062.	1.0	12
260	The Peptidome Comes of Age: Mass Spectrometry-Based Characterization of the Circulating Cancer Peptidome. The Enzymes, 2017, 42, 27-64.	0.7	22
261	Positive feedback of the amphiregulin-EGFR-ERK pathway mediates PM2.5 from wood smoke-induced MUC5AC expression in epithelial cells. Scientific Reports, 2017, 7, 11084.	1.6	31
262	ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells. Scientific Reports, 2017, 7, 9687.	1.6	17
263	ADAM Metalloprotease-Released Cancer Biomarkers. Trends in Cancer, 2017, 3, 482-490.	3.8	16
264	Effects of cigarette smoke extracts on cell cycle, cell migration and endocrine activity in human placental cells. Reproductive Toxicology, 2017, 73, 8-19.	1.3	21
265	Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 2228-2239.	1.9	33
266	Structural Basis for Regulated Proteolysis by the α-Secretase ADAM10. Cell, 2017, 171, 1638-1648.e7.	13.5	121
267	ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype. Tumor Biology, 2017, 39, 101042831771607.	0.8	10
268	Overexpression of A disintegrin and metalloprotease 10 promotes tumor proliferation, migration and poor prognosis in hypopharyngeal squamous cell carcinoma. Oncology Reports, 2017, 38, 866-874.	1.2	3
269	Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate. Journal of Proteomics, 2017, 151, 53-65.	1.2	23
270	Mechanotransduction pulls the strings of matrix degradation at invadosome. Matrix Biology, 2017, 57-58, 190-203.	1.5	15
271	Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-α signalling pathways. Molecular and Cellular Biochemistry, 2017, 426, 17-26.	1.4	20

ARTICLE IF CITATIONS ADAM10-Initiated Release of Notch Intracellular Domain Regulates Microtubule Stability and Radial 272 1.6 14 Migration of Cortical Neurons. Cerebral Cortex, 2017, 27, 919-932. Matrix Metalloproteinases in Cardiovascular Diseases., 2017, , 187-225. Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell 274 0.8 34 frequency. Oncotarget, 2017, 8, 65090-65099. Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates. Journal of Cancer, 2017, 8, 3916-3932. Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells. Oncolmmunology, 2018, 7, 276 2.1 28 e1421889. Comparative analysis of Adam33 mutations in murine lung cancer cell lines by droplet digital PCR, real-time PCR and Insight Oncoâ, ¢ NGS. Molecular and Cellular Toxicology, 2018, 14, 221-231. 0.8 Macrocyclic Î, defensins suppress tumor necrosis factor-l± (TNF-l±) shedding by inhibition of 278 1.6 28 TNF-α–converting enzyme. Journal of Biological Chemistry, 2018, 293, 2725-2734. Phagocyteâ€"extracellular matrix crosstalk empowers tumor development and dissemination. FEBS 279 Journal, 2018, 285, 734-751. 280 Human Umbilical Cord Blood Serum–derived α-Secretase. Cell Transplantation, 2018, 27, 438-455. 1.2 8 Cullin 3 regulates ADAMs-mediated ectodomain shedding of amphiregulin. Biochemical and Biophysical 1.0 Research Communications, 2018, 499, 17-23. Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCFâ€7 cells 282 1.2 5 in $\tilde{A}$ ; $\hat{A}$ ; $\hat{A}$ /2vitro and in $\tilde{A}$ ; $\hat{A}$ /2vivo and its mechanism of action. Oncology Reports, 2018, 39, 1640-1648. Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapiesâ€"A review. 5.0 Medicinal Research Reviews, 2018, 38, 1769-1798. The xenoestrogens biphenolâ€A and nonylphenol differentially regulate metalloproteaseâ€mediated 284 2.0 16 shedding of EGFR ligands. Journal of Cellular Physiology, 2018, 233, 2247-2256. ADAM8 expression in breast cancer derived brain metastases: Functional implications on MMPâ€9 expression and transendothelial migration in breast cancer cells. International Journal of Cancer, 2.3 2018, 142, 779-791. CD9 Controls Integrin  $\hat{l}$  ± 5 $\hat{l}^2$ 1-Mediated Cell Adhesion by Modulating Its Association With the 286 2.2 33 Metalloproteinase ADAM17. Frontiers in Immunology, 2018, 9, 2474. Spindle Checkpoint Regulators in Insulin Signaling. Frontiers in Cell and Developmental Biology, 2018, 1.8 6, 161. ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt 288 1.8 28 signaling pathways. International Journal of Molecular Medicine, 2019, 43, 914-926. Role of platelets and platelet receptors in cancer metastasis. Journal of Hematology and Oncology, 289 370 2018, 11, 125.

#	Article	IF	CITATIONS
290	Dynamic matrisome: ECM remodeling factors licensing cancer progression and metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 207-228.	3.3	102
291	Cellular sheddases are induced by Merkel cell polyomavirus small tumour antigen to mediate cell dissociation and invasiveness. PLoS Pathogens, 2018, 14, e1007276.	2.1	24
292	Targeting Drug Conjugates to the Tumor Microenvironment: Probody Drug Conjugates. Cancer Drug Discovery and Development, 2018, , 281-298.	0.2	8
293	Proteolytic ectodomain shedding of membrane proteins in mammals—hardware, concepts, and recent developments. EMBO Journal, 2018, 37, .	3.5	211
294	Retrograde Degenerative Signaling Mediated by the p75 Neurotrophin Receptor Requires p150Glued Deacetylation by Axonal HDAC1. Developmental Cell, 2018, 46, 376-387.e7.	3.1	23
295	ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker. Journal of Cancer, 2018, 9, 2559-2570.	1.2	30
296	How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive. Frontiers in Immunology, 2018, 9, 262.	2.2	91
297	The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression. International Journal of Molecular Sciences, 2018, 19, 450.	1.8	13
298	From Structure to Phenotype: Impact of Collagen Alterations on Human Health. International Journal of Molecular Sciences, 2018, 19, 1407.	1.8	101
299	Impact of ADAM10 gene polymorphisms on hepatocellular carcinoma development and clinical characteristics. International Journal of Medical Sciences, 2018, 15, 1334-1340.	1.1	12
300	Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes. ChemMedChem, 2018, 13, 2119-2131.	1.6	7
301	Domain integration of ADAM family proteins: Emerging themes from structural studies. Experimental Biology and Medicine, 2019, 244, 1510-1519.	1.1	18
302	Effects of simvastatin on matrix metalloproteinase regulation in IL-1Î <sup>2</sup> -induced SW1353 cells. Chemico-Biological Interactions, 2019, 310, 108730.	1.7	5
303	ADAM proteases: Emerging role and targeting of the non-catalytic domains. Cancer Letters, 2019, 467, 50-57.	3.2	47
304	Pancreatic Ductal Adenocarcinoma: MicroRNAs Affecting Tumor Growth and Metastasis in Preclinical In Vivo Models. Cancer Genomics and Proteomics, 2019, 16, 451-464.	1.0	17
305	ROLES OF MATRIX METALLOPROTEINASES (MMPS) IN CANCER PROGRESSION: A REVIEW. International Research Journal of Pharmacy, 2019, 10, 12-15.	0.0	1
306	The role of proteases in epithelial-to-mesenchymal cell transitions in cancer. Cancer and Metastasis Reviews, 2019, 38, 431-444.	2.7	28
307	ADAM15 mediates upregulation of Claudin-1 expression in breast cancer cells. Scientific Reports, 2019, 9, 12540.	1.6	18

#	Article	IF	CITATIONS
308	Identification of ADAM12 as a Novel Basigin Sheddase. International Journal of Molecular Sciences, 2019, 20, 1957.	1.8	15
309	The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation. Biological Chemistry, 2019, 400, 965-977.	1.2	30
310	Lonomia obliqua bristle extract modulates Rac1 activation, membrane dynamics and cell adhesion properties. Toxicon, 2019, 162, 32-39.	0.8	4
311	ADAM10 sheddase activation is controlled by cell membrane asymmetry. Journal of Molecular Cell Biology, 2019, 11, 979-993.	1.5	48
312	Gamma-secretase-dependent signaling of receptor tyrosine kinases. Oncogene, 2019, 38, 151-163.	2.6	46
313	Enhanced expression of TACE contributes to elevated levels of sVCAM-1 in endometriosis. Molecular Human Reproduction, 2019, 25, 76-87.	1.3	1
314	Astroprincin (FAM171A1, C10orf38). American Journal of Pathology, 2019, 189, 177-189.	1.9	13
315	ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance. Clinical Science, 2019, 133, 83-99.	1.8	51
316	Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 609-619.	3.0	14
317	Monoclonal antibodies against metzincin targets. British Journal of Pharmacology, 2019, 176, 52-66.	2.7	38
318	Metalloproteinases and their roles in human cancer. Anatomical Record, 2020, 303, 1557-1572.	0.8	43
319	Deep profiling of protease substrate specificity enabled by dual random and scanned human proteome substrate phage libraries. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25464-25475.	3.3	28
320	ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. BMC Medicine, 2020, 18, 349.	2.3	8
321	Developments in Carbohydrate-Based Metzincin Inhibitors. Pharmaceuticals, 2020, 13, 376.	1.7	4
322	Editorial: ADAM10 in Cancer Immunology and Autoimmunity: More Than a Simple Biochemical Scissor. Frontiers in Immunology, 2020, 11, 1483.	2.2	3
323	β2â€AR activation promotes cleavage and nuclear translocation of Her2 and metastatic potential of cancer cells. Cancer Science, 2020, 111, 4417-4428.	1.7	11
324	Joint Entropy-Assisted Graphene Oxide-Based Multiplexing Biosensing Platform for Simultaneous Detection of Multiple Proteases. Analytical Chemistry, 2020, 92, 15042-15049.	3.2	18
325	The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators That Inhibit Their Activity. International Journal of Molecular Sciences, 2020, 21, 6805.	1.8	16

#	Article	IF	CITATIONS
326	Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD). International Journal of Molecular Sciences, 2020, 21, 5934.	1.8	28
327	Transcriptomic Bioinformatic Analyses of Atria Uncover Involvement of Pathways Related to Strain and Post-translational Modification of Collagen in Increased Atrial Fibrillation Vulnerability in Intensely Exercised Mice. Frontiers in Physiology, 2020, 11, 605671.	1.3	8
328	Mutational analysis revealed 97 key cancer metastasis genes from extracellular vesicles associated with patient survival. Meta Gene, 2020, 26, 100781.	0.3	0
329	The Physical Microenvironment of Tumors: Characterization and Clinical Impact. Biophysical Reviews and Letters, 2020, 15, 51-82.	0.9	3
330	The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129650.	1.1	22
331	Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. Nature Communications, 2020, 11, 3196.	5.8	43
332	Ab locks for improving the selectivity and safety of antibody drugs. Journal of Biomedical Science, 2020, 27, 76.	2.6	18
333	Propofol affects the growth and metastasis of pancreatic cancer via ADAM8. Pharmacological Reports, 2020, 72, 418-426.	1.5	20
334	ADAM10 is indispensable for longitudinal bone growth in mice. Bone, 2020, 134, 115273.	1.4	4
335	Substrateâ€selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains. FASEB Journal, 2020, 34, 4956-4969.	0.2	22
336	Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding. Journal of Biological Chemistry, 2020, 295, 481-503.	1.6	18
337	MiR-891a-5p as a prognostic marker and therapeutic target for hormone receptor-positive breast cancer. Journal of Cancer, 2020, 11, 3771-3782.	1.2	16
338	Knockdown of N-Acetylglucosaminyltransferase-II Reduces Matrix Metalloproteinase 2 Activity and Suppresses Tumorigenicity in Neuroblastoma Cell Line. Biology, 2020, 9, 71.	1.3	5
339	ADAM15 Participates in Tick-Borne Encephalitis Virus Replication. Journal of Virology, 2021, 95, .	1.5	5
340	ADAM 8 as a novel target for doxorubicin delivery to TNBC cells using magnetic thermosensitive liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 158, 390-400.	2.0	21
341	Expression levels of the metalloproteinase ADAM8 critically regulate proliferation, migration and malignant signalling events in hepatoma cells. Journal of Cellular and Molecular Medicine, 2021, 25, 1982-1999.	1.6	9
342	Targeted truncation of the ADAM17 cytoplasmic domain in mice results in protein destabilization and a hypomorphic phenotype. Journal of Biological Chemistry, 2021, 296, 100733.	1.6	9
343	Elevated inflammatory gene expression in intervertebral disc tissues in mice with ADAM8 inactivated. Scientific Reports, 2021, 11, 1804.	1.6	7

#	Article	IF	CITATIONS
344	Heparan Sulfate-Instructed Self-Assembly Selectively Inhibits Cancer Cell Migration. ACS Applied Materials & Mater	4.0	14
345	Expression of a Disintegrin and Metalloprotease 10 Gene Polymorphisms in a Cohort of Egyptian Patients with Hepatocellular Carcinoma. Current Cancer Therapy Reviews, 2021, 17, .	0.2	0
346	ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease. International Journal of Molecular Sciences, 2021, 22, 4969.	1.8	11
347	Extracellular Matrix Remodeling in Stem Cell Culture: A Potential Target for Regulating Stem Cell Function. Tissue Engineering - Part B: Reviews, 2022, 28, 542-554.	2.5	5
348	Genomic Analysis Revealed Mutational Traits Associated with Clinical Outcomes in Osteosarcoma. Cancer Management and Research, 2021, Volume 13, 5101-5111.	0.9	1
349	ECM Remodeling in Squamous Cell Carcinoma of the Aerodigestive Tract: Pathways for Cancer Dissemination and Emerging Biomarkers. Cancers, 2021, 13, 2759.	1.7	4
350	Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect. Haematologica, 2021, , .	1.7	9
351	Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model. Acta Biomaterialia, 2021, 132, 401-420.	4.1	9
352	Posttranslational modifications by ADAM10 shape myeloid antigen-presenting cell homeostasis in the splenic marginal zone. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	7
353	ADAM17 mediates ectodomain shedding of the soluble VLDL receptor fragment in the retinal epithelium. Journal of Biological Chemistry, 2021, 297, 101185.	1.6	8
354	Aberrant Methylation of Tumour Suppressor Gene ADAM12 in Chronic Lympocytic Leukemia Patients: Application of Methylation Specific-PCR Technique. Asian Pacific Journal of Cancer Prevention, 2021, 22, 85-91.	0.5	2
355	Proteases from Inflammatory Cells: Regulation of Inflammatory Response. , 2011, , 73-100.		1
356	Haemoglobin Scavenging After Subarachnoid Haemorrhage. Acta Neurochirurgica Supplementum, 2015, 120, 51-54.	0.5	15
357	Proteases in Melanoma. , 2011, , 165-179.		1
358	Proteases in Cancer: Significance for Invasion and Metastasis. , 2013, , 491-550.		10
359	ADAM Proteases in Physiology and Pathophysiology: Cleave to Function in Health or to Cause Disease. , 2013, , 303-318.		3
360	Structural Aspects of the Factor X Activator RVV-X from Russell's Viper Venom. , 2010, , 465-484.		6
361	Matrix Metalloproteinases (MMPs) in Cancer Initiation and Progression. , 2017, , 207-236.		1

#	Article	IF	CITATIONS
362	Necroptosis, ADAM proteases and intestinal (dys)function. International Review of Cell and Molecular Biology, 2020, 353, 83-152.	1.6	5
364	Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell–derived ADAM9. JCI Insight, 2016, 1, e88245.	2.3	90
365	LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through HB-EGF Shedding and EGFR-Mediated ERK Signaling. PLoS ONE, 2011, 6, e27720.	1.1	94
366	Interleukin-1 Stimulates ADAM17 through a Mechanism Independent of its Cytoplasmic Domain or Phosphorylation at Threonine 735. PLoS ONE, 2012, 7, e31600.	1.1	43
367	Characterization of CD200 Ectodomain Shedding. PLoS ONE, 2016, 11, e0152073.	1.1	16
368	CD83 is locally regulated and differentially expressed in disturbed murine pregnancy. Reproduction, 2019, 158, 323-333.	1.1	7
369	AHNAK enables mammary carcinoma cells to produce extracellular vesicles that increase neighboring fibroblast cell motility. Oncotarget, 2016, 7, 49998-50016.	0.8	50
370	Suppression of LPS-induced inflammatory responses by the hydroxyl groups of dexamethasone. Oncotarget, 2017, 8, 49735-49748.	0.8	21
371	Targeting CD13 (aminopeptidase-N) in turn downregulates ADAM17 by internalization in acute myeloid leukaemia cells. Oncotarget, 2014, 5, 8211-8222.	0.8	12
372	Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas. Oncotarget, 2015, 6, 24002-24016.	0.8	59
373	ADAM Metalloproteinases as Potential Drug Targets. Current Medicinal Chemistry, 2019, 26, 2661-2689.	1.2	20
374	Age-related Macular Degeneration: Current Knowledge of Zinc Metalloproteinases Involvement. Current Drug Targets, 2019, 20, 903-918.	1.0	3
375	Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling. Asian Pacific Journal of Cancer Prevention, 2017, 18, 905-915.	0.5	28
376	A Brief History of Tumor Necrosis Factor α – converting Enzyme: An Overview of Ectodomain Shedding. Keio Journal of Medicine, 2013, 62, 29-36.	0.5	34
377	ADAM9 Expression in Uterine Cervical Cancer and Its Associated Factors. Asian Pacific Journal of Cancer Prevention, 2019, 20, 1081-1087.	0.5	11
378	A Disintegrin and Metalloproteinase—Control Elements in Infectious Diseases. Frontiers in Cardiovascular Medicine, 2020, 7, 608281.	1.1	11
379	Luteolin alters MUC1 extracellular domain, sT antigen, ADAMâ€ʿ17, ILâ€ʿ8, ILâ€ʿ10 and NFâ€ʿîºB expression in <i>Helicobacter</i> Â <i>pylori</i> â€ʿinfected gastric cancer CRLâ€ʿ1739 cells: A preliminary study. Biomedical Reports, 2020, 14, 19.	0.9	15
380	Extracellular matrix remodeling in human disease. Journal of Microscopy and Ultrastructure, 2018, 6, 123.	0.1	71

щ		IC	CITATIONS
#	Inhibitory effects of oroxylin A on endothelial protein C receptor shedding in vitro and in vivo. BMB	11	CHATIONS
381	Reports, 2014, 47, 336-341.	1,1	48
382	Inhibitory effects of lysozyme on endothelial protein C 1receptor shedding in vitro and in vivo. BMB Reports, 2015, 48, 624-629.	1.1	32
383	Brain Metastases Progression of Breast Cancer. , 0, , .		3
384	The nine ADAMs family members serve as potential biomarkers for immune infiltration in pancreatic adenocarcinoma. PeerJ, 2020, 8, e9736.	0.9	9
385	The pseudoprotease iRhom1 controls ectodomain shedding of membrane proteins in the nervous system. FASEB Journal, 2021, 35, e21962.	0.2	5
386	Biological Activities of Snake Venom Metalloproteinases on Platelets, Neutrophils, Endothelial Cells, and Extracellular Matrices. , 2010, , 723-732.		0
387	Tumor Microenvironment. , 2010, , 27-69.		1
389	ADAM28., 2013, , 1136-1139.		0
390	The ADAMs: New Therapeutic Targets for Cancer?. , 2013, , 273-287.		0
391	ADAM8/MS2/CD156a. , 2013, , 1094-1101.		0
392	Proteases and Their Role in Drug Development with an Emphasis in Cancer. , 2014, , 227-244.		0
393	CHAPTER 6. Identification and Localization of Post-Translational Modifications by High-Resolution Mass Spectrometry. New Developments in Mass Spectrometry, 2016, , 116-132.	0.2	0
394	Proteases in Melanoma. , 2017, , 209-226.		1
395	ADAM and ADAMTS Family of Metalloproteinases: Role in Cancer Progression and Acquisition of Hallmarks. , 2017, , 303-331.		0
396	Metalloproteinases: a Functional Pathway for Myeloid Cells. , 0, , 649-658.		0
397	The role of matrix metalloproteinases in cancer progression, in particular metastasis. Archives of Medical Science - Civilization Diseases, 2018, 3, 124-146.	0.1	2
398	Phosphorylation of iRhom2 Is Essential for Stimulated Proteolytic Shedding by the Metalloprotease ADAM17/TACE. SSRN Electronic Journal, 0, , .	0.4	0
399	Research Progress of ADAM9 in the Biology of Solid Tumors. Advances in Clinical Medicine, 2020, 10, 2270-2280.	0.0	0

#	Article	IF	Citations
401	Expression of ADAM29 and FAM135B in the pathological evolution from normal esophageal epithelium to esophageal cancer: Their differences and clinical significance. Oncology Letters, 2020, 19, 1727-1734.	0.8	3
402	ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 13279-83.	0.5	10
403	Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells. Translational Oncology, 2022, 15, 101265.	1.7	8
404	Visualization and Quantification of the Extracellular Matrix in Prostate Cancer Using an Elastin Specific Molecular Probe. Biology, 2021, 10, 1217.	1.3	2
405	Propofol induces apoptosis and ameliorates 5‑fluorouracil resistance in OSCC cells by reducing the expression andÂsecretion of amphiregulin. Molecular Medicine Reports, 2021, 25, .	1.1	4
406	Influence of Anoctamin-4 and -9 on ADAM10 and ADAM17 Sheddase Function. Membranes, 2022, 12, 123.	1.4	6
407	In Silico and Experimental ADAM17 Kinetic Modeling as Basis for Future Screening System for Modulators. International Journal of Molecular Sciences, 2022, 23, 1368.	1.8	4
408	Scramblases as Regulators of Proteolytic ADAM Function. Membranes, 2022, 12, 185.	1.4	8
409	Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis. Journal of Experimental Medicine, 2022, 219, .	4.2	35
411	An Introduction to Bacterial Biofilms and Their Proteases, and Their Roles in Host Infection and Immune Evasion. Biomolecules, 2022, 12, 306.	1.8	21
412	Into the Tissues: Extracellular Matrix and Its Artificial Substitutes: Cell Signalling Mechanisms. Cells, 2022, 11, 914.	1.8	38
413	Human B Cells Mediate Innate Anti-Cancer Cytotoxicity Through Concurrent Engagement of Multiple TNF Superfamily Ligands. Frontiers in Immunology, 2022, 13, 837842.	2.2	8
414	The Metalloprotease-Disintegrin ADAM8 Alters the Tumor Suppressor miR-181a-5p Expression Profile in Glioblastoma Thereby Contributing to Its Aggressiveness. Frontiers in Oncology, 2022, 12, 826273.	1.3	11
415	Met inhibitors in the treatment of lung cancer: the evidence to date. Expert Opinion on Pharmacotherapy, 2022, , .	0.9	Ο
422	Tissue remodeling by an opportunistic pathogen triggers allergic inflammation. Immunity, 2022, 55, 895-911.e10.	6.6	19
424	Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours. Cancers, 2022, 14, 3171.	1.7	2
425	A Disintegrin and Metalloprotease 10 Expressions Modulate Potential Metastatic and Thrombus Formation in Pancreatic Carcinoma. Iranian Journal of Public Health, 0, , .	0.3	1
426	Cancer – Proteases in Progression and Metastasis. , 2022, ,		0

#	Article	IF	CITATIONS
427	Tetraspanin 8 Subfamily Members Regulate Substrate-Specificity of a Disintegrin and Metalloprotease 17. Cells, 2022, 11, 2683.	1.8	4
428	Proteolytic modulation of tumor microenvironment signals during cancer progression. Frontiers in Oncology, 0, 12, .	1.3	6
429	Newfound Coding Potential of Transcripts Unveils Missing Members of Human Protein Communities. Genomics, Proteomics and Bioinformatics, 2023, 21, 515-534.	3.0	2
430	ADAM10 and ADAM17—Novel Players in Retinoblastoma Carcinogenesis. International Journal of Molecular Sciences, 2022, 23, 12621.	1.8	0
432	ADAM10 mediates shedding of carbonic anhydrase IX ectodomain non‑redundantly to ADAM17. Oncology Reports, 2022, 49, .	1.2	2
433	The immunological role of ADAMs in the field of gastroenterological chronic inflammatory diseases and cancers: a review. Oncogene, 2023, 42, 549-558.	2.6	2
434	ADAM10 Gene Polymorphism and Its Relationship to Hepatocellular Carcinoma in Egyptian HCV Patients Receiving Direct-Acting Antiviral Therapies (DAAs). Asian Pacific Journal of Cancer Prevention, 2023, 24, 149-155.	0.5	0
435	Dysregulation of ADAM10 shedding activity in naked moleâ€rat fibroblasts is due to deficient phosphatidylserine externalization. Journal of Cellular Physiology, 0, , .	2.0	0
436	Nanopore single-molecule analysis of biomarkers: Providing possible clues to disease diagnosis. TrAC - Trends in Analytical Chemistry, 2023, 162, 117060.	5.8	5
437	Fully human monoclonal antibody targeting activated ADAM10 on colorectal cancer cells. Biomedicine and Pharmacotherapy, 2023, 161, 114494.	2.5	3
438	The versatile roles of ADAM8 in cancer cell migration, mechanics, and extracellular matrix remodeling. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	6
439	Matrixâ€Metalloproteinase Inhibitory Study of Novel Tetrahydroisoquinolineâ€4â€carboxylates: Design, Synthesis, and Molecular Docking studies Chemistry and Biodiversity, 0, , .	1.0	0